PureTech acquires LYT-100 to treat lymphedema

PureTech Health has announced that it has acquired and plans to develop a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema.The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies and was observed to be well tolerated with a favourable pharmacokinetic profile to support twice daily oral dosing. The oral, small molecule candidate expands PureTech’s internal R&D pipeline and continues its progress in developing new medicines based on insights into the lymphatic system and local modulation of the immune system for the treatment of immune and central nervous system disorders, lymphatic conditions, and cancers. The current standards of care for lymphedema – compression and physical therapy – are cumbersome and non-curative approaches that cannot correct immune cell infiltration or regenerate the dysregulated lymphatics. “Lymphedema is a chronic and incurable secondary disease affecting millions of people, and there has been far too little progress made toward the development of meaningful treatments,” said Joe Bolen, chief scientific officer of PureTech.